What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Surgery
- Disease
Her scientific interests lie mostly in Internal medicine, Rheumatoid arthritis, Surgery, Ankylosing spondylitis and Randomized controlled trial.
The study incorporates disciplines such as Placebo and Physical therapy in addition to Internal medicine.
Her Rheumatoid arthritis research is multidisciplinary, relying on both Methotrexate, Gastroenterology, Erythrocyte sedimentation rate, Connective tissue disease and Combination therapy.
Her research in Surgery intersects with topics in Epidemiology, Infliximab and Immunopathology.
The concepts of her Ankylosing spondylitis study are interwoven with issues in BASDAI, Clinical trial, Cohort and Syndesmophyte.
The various areas that Désirée van der Heijde examines in her Randomized controlled trial study include Physical exercise, Functional ability, Adverse effect and Disease-modifying antirheumatic drug.
Her most cited work include:
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (3784 citations)
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial (1047 citations)
- Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis (985 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Internal medicine, Rheumatoid arthritis, Ankylosing spondylitis, Physical therapy and Rheumatology.
Her Internal medicine research includes themes of Gastroenterology, Placebo and Surgery.
Her Rheumatoid arthritis course of study focuses on Radiography and Joint damage.
Her study in the field of Spondylitis also crosses realms of In patient.
Désirée van der Heijde focuses mostly in the field of Physical therapy, narrowing it down to topics relating to Clinical trial and, in certain cases, Observational study.
Her study in Rheumatology is interdisciplinary in nature, drawing from both Orthopedic surgery, Pathology and Rheumatoid factor.
She most often published in these fields:
- Internal medicine (58.91%)
- Rheumatoid arthritis (33.87%)
- Ankylosing spondylitis (33.07%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (58.91%)
- Ankylosing spondylitis (33.07%)
- Axial spondyloarthritis (14.61%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Internal medicine, Ankylosing spondylitis, Axial spondyloarthritis, Radiography and Rheumatoid arthritis.
Her work on Rheumatology, Cohort and Spondylitis as part of general Internal medicine study is frequently linked to In patient, bridging the gap between disciplines.
Her Ankylosing spondylitis research is multidisciplinary, relying on both Quality of life, BASDAI, Syndesmophyte, Severity of illness and Confounding.
The concepts of her Axial spondyloarthritis study are interwoven with issues in Physical therapy, Certolizumab pegol and Family medicine.
The study incorporates disciplines such as Rheumatism, Methotrexate, Disease and Arthritis in addition to Rheumatoid arthritis.
Her work focuses on many connections between Placebo and other disciplines, such as Randomized controlled trial, that overlap with her field of interest in Tofacitinib.
Between 2017 and 2021, her most popular works were:
- Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (293 citations)
- TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort (138 citations)
- Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. (130 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
Désirée van der Heijde mainly focuses on Internal medicine, Ankylosing spondylitis, Placebo, Rheumatoid arthritis and In patient.
Her research links Radiography with Internal medicine.
Her Ankylosing spondylitis research is multidisciplinary, incorporating perspectives in Magnetic resonance imaging, Axial spondyloarthritis, Severity of illness and Outcomes research.
The Placebo study combines topics in areas such as Randomized controlled trial, Antibody and Phases of clinical research.
Her research integrates issues of Rheumatism, Methotrexate, Disease and Intensive care medicine in her study of Rheumatoid arthritis.
Her Clinical trial research includes elements of Psoriatic arthritis, Arthritis and Adverse effect.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
